These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14609245)

  • 21. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
    J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients.
    Swanson J; Van Dorn RA; Swartz MS
    Schizophr Res; 2007 Aug; 94(1-3):114-8. PubMed ID: 17587548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.
    Yamashita H; Mori K; Nagao M; Okamoto Y; Morinobu S; Yamawaki S
    Am J Geriatr Psychiatry; 2005 May; 13(5):377-84. PubMed ID: 15879586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.
    Law MR; Soumerai SB; Ross-Degnan D; Adams AS
    J Clin Psychiatry; 2008 Jan; 69(1):47-53. PubMed ID: 18312037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.
    Kumari V; Ettinger U; Lee SE; Deuschl C; Anilkumar AP; Schmechtig A; Corr PJ; Ffytche DH; Williams SC
    Psychopharmacology (Berl); 2015 Sep; 232(17):3135-47. PubMed ID: 25980483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H; Osuntokun OO; Feldman PD
    Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting.
    Cook PE; Goldberg JO; Van Lieshout RJ
    Can J Psychiatry; 2002 Nov; 47(9):870-4. PubMed ID: 12500758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications.
    Sernyak MJ; Leslie D; Rosenheck R
    Am J Psychiatry; 2003 Feb; 160(2):310-5. PubMed ID: 12562578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
    Jerrell JM
    Schizophr Bull; 2002; 28(4):589-605. PubMed ID: 12795493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.